<p>Spruce Biosciences Inc. has approved a stock option repricing plan, effective December 11, 2025. Under this plan, the exercise price of certain outstanding stock options held by employees and directors, including executive officers, has been reduced to the market price of the company’s common stock as of the effective date. The repriced options will only become exercisable at the reduced price after a designated retention period, which lasts up to twelve months, until FDA approval of the company’s tralesinidase alfa product candidate, or a change in control, whichever occurs first. The repriced options include 11,666 options for CEO Javier Szwarcberg and 6,131 options for CFO Samir Gharib. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-317532), on December 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

SPRB

SPRBD

<p>Spruce Biosciences Inc. has approved a stock option repricing plan effective December 11, 2025, reducing exercise prices to market value. Options become exercisable after a retention period or upon FDA approval of tralesinidase alfa or a change in control. CEO Javier Szwarcberg and CFO Samir Gharib are among those affected. This move aims to boost employee retention.</p>

Spruce Biosciences Reprices Stock Options to Boost Employee Retention